Journal of Neurology

, Volume 253, Supplement 5, pp v2–v8

Epidemiology of neuroimmunological diseases

Abstract

This review gives an overview of various neuroimmunological diseases in terms of incidence and prevalence rates, age and sex distribution, and the frequency of subtypes, if applicable. The disorders selected for review are inflammatory muscle disorders (polymyositis, dermatomyositis and inclusion body myositis), myasthenia gravis, immune-mediated polyneuropathies (Guillain-Barré syndrome, chronic polyneuritis and vasculitic neuropathies), and multiple sclerosis.

Key words

epidemiology inflammatory muscle diseases myasthenia gravis Guillain-Barré syndrome multiple sclerosis MS register 

References

  1. 1.
    Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I (2003) Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 60(6):1024–1026PubMedGoogle Scholar
  2. 2.
    Arnason BG, Soliven B (1993) Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) Peripheral neuropathy. WB, Saunders, Philadelphia, pp 1437–1497Google Scholar
  3. 3.
    Badrising UA, Maat-Schiemann M, van Duinen SG et al. (2000) Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55:1385–1387PubMedGoogle Scholar
  4. 4.
    Busby M, Donaghy M (2003) Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 250:714–724PubMedCrossRefGoogle Scholar
  5. 5.
    Cheng Q, Jiang GX, Fredrikson S (2000) Incidence of Guillain-Barré syndrome in Sweden 1996. Eur J Neurol 7:11–16PubMedCrossRefGoogle Scholar
  6. 6.
    Collins MP, Periquet MI (2004) Non-systemic vasculitic neuropathy. Curr Opin Neurol 17:587–598PubMedCrossRefGoogle Scholar
  7. 7.
    Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231PubMedCrossRefGoogle Scholar
  8. 8.
    Dalakas MC (2004) Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17:561–567PubMedCrossRefGoogle Scholar
  9. 9.
    Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982PubMedCrossRefGoogle Scholar
  10. 10.
    Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797–1810PubMedCrossRefGoogle Scholar
  11. 11.
    Dyck PJ, Benstead TJ, Conn DL et al. (1987) Nonsystemic vasculitic neuropathy. Brain 110:843–853PubMedGoogle Scholar
  12. 12.
    Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology (1997) A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992–1993). Neurology 48:214–221Google Scholar
  13. 13.
    Flachenecker P, Zettl UK (2005) Epidemiologie. In: Schmidt RM, Hoffmann F (eds) Multiple Sklerose. Urban and Fischer, München, pp 9–15Google Scholar
  14. 14.
    Flachenecker P, Zettl UK, Götze U, Haas J, Schimrigk S, Elias W, Pette M, Eulitz M, Hennig M, Bertram J, Hollweck R, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P (2005) MS-Register in Deutschland—Design und erste Ergebnisse der Pilotphase. Nervenarzt 76:967–975PubMedCrossRefGoogle Scholar
  15. 15.
    Govoni V, Granieri E (2001) Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol 14:605–613PubMedCrossRefGoogle Scholar
  16. 16.
    Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT (2004) Guillain-Barre syndrome following influenza vaccination. JAMA 292:2478–2481PubMedCrossRefGoogle Scholar
  17. 17.
    Hartung HP, Kieseier BC, Kiefer R (2001) Progress in Guillain-Barré syndrome. Curr Opin Neurol 14:597–604PubMedCrossRefGoogle Scholar
  18. 18.
    Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome—Part I Muscle Nerve 18:137–153PubMedCrossRefGoogle Scholar
  19. 19.
    Hein T, Hopfenmüller W (2000) Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland. Nervenarzt 71:288–294PubMedCrossRefGoogle Scholar
  20. 20.
    Hohlfeld R, Wekerle H (1994) The thymus in myasthenia gravis. Neurol Clin 12:331–342PubMedGoogle Scholar
  21. 21.
    Hovi T, Stenvik M (2000) Surveillance of patients with acute flaccid paralysis in Finland: report of a pilot study. Bull World Health Organ 78:298–304PubMedGoogle Scholar
  22. 22.
    Hunder GG, Arend WP, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067PubMedCrossRefGoogle Scholar
  23. 23.
    Jennette JC, Falk RJ,Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedGoogle Scholar
  24. 24.
    Jiang GX, Cheng Q, Link H, de Pedro-Cuesta J (1997) Epidemiological features of Guillain-Barré syndrome in Sweden, 1978–1993. J Neurol Neurosurg Psychiatry 62:447–453PubMedGoogle Scholar
  25. 25.
    Kaida K, Kusunoki S, Kamakura K et al. (2000) Guillain-Barré syndrome with antibody to a ganglioside, Nacetylgalactosaminyl GD1a. Brain 123:116–124PubMedCrossRefGoogle Scholar
  26. 26.
    Keegan BM, Noseworthy JH (2002) Multiple sclerosis. Annu Rev Med 53:285–302PubMedCrossRefGoogle Scholar
  27. 27.
    Kissel JT (2001) Vasculitic neuropathies. In: Gilman S (ed) MedLink Neurology. MedLink Corporation, San DiegoGoogle Scholar
  28. 28.
    Kurtzke JF (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382–427PubMedGoogle Scholar
  29. 29.
    Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT (1998) The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797–1802PubMedCrossRefGoogle Scholar
  30. 30.
    Léger JM, Behin A (2005) Multifocal motor neuropathy. Curr Opin Neurol 18:567–573PubMedGoogle Scholar
  31. 31.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911PubMedGoogle Scholar
  32. 32.
    Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423PubMedCrossRefGoogle Scholar
  33. 33.
    Martyn C (1991) The epidemiology of multiple sclerosis. In: Matthews WB (ed) McAlpines’s multiple sclerosis. Churchill Livingstone, New York, pp 3–40Google Scholar
  34. 34.
    Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M (2003) Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 61:1373–1377PubMedGoogle Scholar
  35. 35.
    Meyer-Rienecker H, Buddenhagen F (1988) Incidence of multiple sclerosis: a periodic or stable phenomenon. J Neurol 235:241–244 PubMedCrossRefGoogle Scholar
  36. 36.
    Mygland A, Monstad P (2001) Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 8:157–165PubMedCrossRefGoogle Scholar
  37. 37.
    Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17:599–605PubMedCrossRefGoogle Scholar
  38. 38.
    Oldflors A, Lindberg C (2005) Diagnosis, pathogenesis and treatment of inclusion body myositis. Curr Opin Neurol 18:497–503CrossRefGoogle Scholar
  39. 39.
    Olney RK, Lewis RA, Putnam TD, Campellone RV (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117–121PubMedCrossRefGoogle Scholar
  40. 40.
    Palace J, Vincent A, Beeson D (2001) Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol 14:583–589PubMedCrossRefGoogle Scholar
  41. 41.
    Phillips BA, Zilko PJ, Mastaglia FL (2000) Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 23:970–972PubMedCrossRefGoogle Scholar
  42. 42.
    Phillips LH (2004) The epidemiology of myasthenia gravis. Semin Neurol 24:17–20PubMedCrossRefGoogle Scholar
  43. 43.
    Pinching AJ, Peters DK, Newsom Davis J (1976) Remission of myasthenia gravis following plasma exchange. Lancet 2:1373–1376PubMedCrossRefGoogle Scholar
  44. 44.
    Poser CM (1994) The epidemiology of multiple sclerosis: a general overview. Ann Neurol 36(Suppl 2):S180–S193PubMedCrossRefGoogle Scholar
  45. 45.
    Potagas C, Dellatolas G, Tavernarakis A, Molari H, Mourtzouhou P, Koutra H, Matikas N, Balakas N (2004) Myasthenia gravis: changes observed in a 30-years retrospective clinical study of a hospital-based population. J Neurol 251:116–117PubMedCrossRefGoogle Scholar
  46. 46.
    Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333:1374–1379PubMedCrossRefGoogle Scholar
  47. 47.
    Saperstein DS, Katz JS, Amato AA, Barohn RJ (2001) Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24:311–324PubMedCrossRefGoogle Scholar
  48. 48.
    Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. (1979) Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol 110:105PubMedGoogle Scholar
  49. 49.
    Sommer C, Heuss D, Schlotter-Weigel B, Engelhardt A, Reinhold-Keller E (2003) Diagnostik und Therapie der vaskulitischen Neuropathien und Neuropathien bei Kollagenosen. In: Diener HC, für die Kommission „Leitlinien“ der Deutschen Gesellschaft für Neurologie (eds) Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme Verlag, Stuttgart New York, pp 263–273Google Scholar
  50. 50.
    Teixeira A, Cherin P, Demoule A et al. (2005) Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 15:32–39PubMedCrossRefGoogle Scholar
  51. 51.
    Toyka KV, Drachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190:397–399PubMedGoogle Scholar
  52. 52.
    van der Meulen MFG, Bonner M, Hoogendijk JE et al. (2003) Polymyositis: a diagnostic entity reconsidered. Neurology 61:316–321PubMedGoogle Scholar
  53. 53.
    van Doorn PA, Ruts L (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17:607–613PubMedCrossRefGoogle Scholar
  54. 54.
    van Koningsveld R, van Doorn PA, Schmitz PIM et al. (2000) Mild forms of Guillain-Barré syndrome in an epidemiological survey in the Netherlands. Neurology 54:620–625PubMedGoogle Scholar
  55. 55.
    Viala K, Renie T, Maisonobe T et al. (2004) Follow-up and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127:2010–2017PubMedCrossRefGoogle Scholar
  56. 56.
    Voermans NC, Vaneker M, Hengstman GJ et al. (2004) Primary respiratory failure in inclusion body myositis. Neurology 63:2191–2192PubMedGoogle Scholar
  57. 57.
    Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112:133–146PubMedGoogle Scholar
  58. 58.
    Willison HJ, Veitch J, Paterson G, Kennedy PGE (1993) Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 56:204–206PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  1. 1.Neurological Rehabilitation Center „Quellenhof“Bad WildbadGermany

Personalised recommendations